2 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Unresectable Cholangiocarcinoma: new trials by email Literature Review of Unresectable Cholangiocarcinoma trials Research Report on Unresectable Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine, Ivosidenib - Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 1 | Terminated | Academic and Community Cancer Research United | 8 | 2021-01-25 | 2024-05-06 |
| Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study. Neoadjuvant Chemo-radiotherapy, Liver Transplantation - Unresectable Cholangiocarcinoma | Recruiting | Hospital Vall d'Hebron | 34 | 2020-04-24 | 2026-05-26 | |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Carboplatin, Paclitaxel, Pevonedistat - Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2020-03-16 | 2026-10-26 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma Pemigatinib, Gemcitabine, Cisplatin - Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 3 | Terminated | Incyte Corporation | 167 | 2019-06-03 | 2026-08-11 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Entinostat, Nivolumab - Metastatic Cholangiocarcinoma, Cholangiocarcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 44 | 2017-11-06 | 2025-05-28 |
| Photodynamic Therapy (PDT) Cholangiocarcinoma Registry Photodynamic Therapy - Unresectable Cholangiocarcinoma, Biliary Obstruction | Unknown | Weill Medical College of Cornell University | 200 | 2011-11-01 | 2017-02-20 |
Cholangiocarcinoma (6) · Carcinoma, Hepatocellular (1) · Gallbladder Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Adenocarcinoma (6) · Carcinoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms by Site (3) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gallbladder Diseases (1) · Liver Diseases (1) · Liver Neoplasms (1)
pemigatinib (3) · Cisplatin (2) · Gemcitabine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 1-phenyl-3,3-dimethyltriazene (1) · Biopsy (1) · Carboplatin (1) · Liver Transplantation (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Paclitaxel (1) · Photochemotherapy (1) · Platinum (1) · Specimen Handling (1) · Taxes (1)
Incyte Corporation (2) · National Cancer Institute (NCI) (2) · Academic and Community Cancer Research United (1) · Hospital Vall d'Hebron (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Weill Medical College of Cornell University (1)
United States (6) · Spain (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Carmelo Loinaz-Segurola (1) · Carmen Bernardo (1) · Dustin A Deming (1) · Jaume Capdevila (1)
PMID 11573044, PMID 15192792, PMID 16135931, PMID 22504095, PMID 29064885, PMID 32677452, PMID 34907910, PMID 39532835, PMID 39932259, PMID 41678089, PMID 42223137
2018 (1), 2025 (1), P01CA247886 (1), P30CA015083 (1), U10CA180820 (1), UM1CA186691 (1)